---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-050158"
form_type: "8-K"
ticker: "OMDA"
cik: "0001611115"
company_name: "Omada Health, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:42:48.300952+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Omada Health Q3 revenue $68M (+49% YoY); first positive adjusted EBITDA $2M

## Summary
- Revenue $68M, up 49% YoY; members 831K, up 53% YoY.
- Net loss $3M vs $9M loss prior year; first quarter of positive adjusted EBITDA of $2M.
- Gross margin 66% (non-GAAP 68%), up from 63% (65%) in Q3 2024.
- Announced new GLP-1 prescribing offering combining behavior change with anti-obesity medications.
- Cash and equivalents $199M at quarter end.

## SEC filing metadata
- accession: 0001628280-25-050158
- form_type: 8-K
- ticker: OMDA
- cik: 0001611115
- company_name: Omada Health, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1611115/000162828025050158/0001628280-25-050158-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1611115/000162828025050158/omda-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-050158
- JSON: https://secwatch.observer/filing/0001628280-25-050158.json
- Plain text: https://secwatch.observer/filing/0001628280-25-050158.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.